These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3742899)

  • 1. [Hallucinatory symptoms in Parkinson's disease during treatment with anti-parkinsonian drugs].
    Nagano O; Takauchi S; Nishitani H; Miyoshi K
    Rinsho Shinkeigaku; 1986 May; 26(5):464-70. PubMed ID: 3742899
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tactile hallucinations induced by trihexyphenidyl in a patient with Parkinson's disease].
    Funakawa I; Jinnai K
    Rinsho Shinkeigaku; 2005 Feb; 45(2):125-7. PubMed ID: 15782612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease.
    Gondim Fde A; Costa HA; Taunay TC; de Oliveira GR; Ferreira JM; Rola FH
    Mov Disord; 2010 Jul; 25(10):1505-6. PubMed ID: 20629118
    [No Abstract]   [Full Text] [Related]  

  • 5. Delusional infestation induced by piribedil add-on in Parkinson's disease.
    Kölle M; Lepping P; Kassubek J; Schönfeldt-Lecuona C; Freudenmann RW
    Pharmacopsychiatry; 2010 Aug; 43(6):240-2. PubMed ID: 20614418
    [No Abstract]   [Full Text] [Related]  

  • 6. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
    Papapetropoulos S; Argyriou AA
    Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
    [No Abstract]   [Full Text] [Related]  

  • 7. An artist's view of drug-induced hallucinosis.
    Ebersbach G
    Mov Disord; 2003 Jul; 18(7):833-4. PubMed ID: 12815666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hallucinations in Parkinson's disease: the clinical syndrome.
    Goetz CG
    Adv Neurol; 1999; 80():419-23. PubMed ID: 10410750
    [No Abstract]   [Full Text] [Related]  

  • 9. Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?
    Kataoka H; Sawa N; Sugie K; Ueno S
    J Neurol Sci; 2014 Dec; 347(1-2):361-3. PubMed ID: 25454646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma amantadine concentrations in patients with Parkinson's disease.
    Nishikawa N; Nagai M; Moritoyo T; Yabe H; Nomoto M
    Parkinsonism Relat Disord; 2009 Jun; 15(5):351-3. PubMed ID: 18823813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Between Scylla and Charybdis: drug-induced psychosis in patients with Parkinson disease].
    Kuiper MA; Zwaan WA; Wolters EC
    Ned Tijdschr Geneeskd; 1994 Jul; 138(27):1353-7. PubMed ID: 8035892
    [No Abstract]   [Full Text] [Related]  

  • 13. Medication-induced hallucination and cerebral blood flow in Parkinson's disease.
    Okada K; Suyama N; Oguro H; Yamaguchi S; Kobayashi S
    J Neurol; 1999 May; 246(5):365-8. PubMed ID: 10399867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease.
    de la Fuente-Fernández R; Núñez MA; López E
    Clin Neuropharmacol; 1999; 22(4):226-30. PubMed ID: 10442253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of hallucinations induced by long-term drug therapy.
    Goetz CG; Tanner CM; Klawans HL
    Am J Psychiatry; 1982 Apr; 139(4):494-7. PubMed ID: 6802003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Parkinson's disease in Spain.
    Grandas F; Kulisevsky J
    Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Emotional and cognitive disorders in Parkinson disease].
    Arsland D; Larsen JP
    Tidsskr Nor Laegeforen; 1998 Oct; 118(25):3959-63. PubMed ID: 9830342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.